Eli Lilly’s EBGLYSS Receives FDA Approval for Patients 12 and Above with Moderate-to-Severe Atopic DermatitisÂ
Eli Lilly has announced that EBGLYSS â„¢ (lebrikizumab-lbkz) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis in adults and children






